Earth Science Tech (OTC: ETST), a strategic holding company, operates a portfolio in the pharmaceutical, telemedicine, healthcare and consumer markets. The company strives to build value by acquiring and actively managing businesses and focuses on controlling interests in companies where regulatory compliance, operational oversight, and disciplined scaling can drive growth.
Earth Science Tech takes an approach that prioritizes capital discipline, execution, and long-term value creation across the platforms it operates, while focusing on scaling businesses that can grow sustainably and increase shareholder value.
The wholly owned and majority-owned subsidies that the company operates includes:
The team at Earth Science Tech is led by CEO and Chairman of the Board, Giorgio R. Saumat. Saumat is an investor and entrepreneur with more than 20 years of experience in investing, operating, and consulting for private businesses and investors.
The company’s CFO is Ernesto L. Flores, a financial executive with more than a decade of experience in financial management, taxation, and accounting. He’s held senior roles at logistics and investment firms, where he oversaw compliance and financial operations.
Other members of the leadership team include President and COO Mario G. Tabraue, who has experience across real estate operations and digital infrastructure, and CTO Christopher Rose, who is a tech and automation executive who previously led automation initiatives at a Fortune 100 company.
For more information, visit EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Most cancer patients report cognitive deterioration, such as memory loss and difficulty concentrating as they…
Voice Analytics and AI to Transform Drug and Alcohol Testing Disseminated on behalf of MindBio Therapeutics…
Oncotelic’s PDAOAI platform indexes 125,000+ PubMed abstracts on TGF-β signaling, enabling researchers to interrogate the…
The scale and impact of cardiovascular disease underscore why innovation in this area is so…
At the core of Cardio Diagnostics’ approach is the use of artificial intelligence to integrate…
Last fall, Johns Hopkins School of Nursing through its Institute for Policy Solutions conducted a survey on health inequities…